Bayer, Onyx Phase III NSCLC trial fails to meet primary endpoint

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that Phase III trial of Nexavar  in non-small cell lung cancer patients did not meet primary endpoint of improving overall survival.

The Monotherapy admInistration of Sorafenib in patientS wIth nOn-small cell luNg cancer trial observed an improvement in the secondary endpoint of progression-free survival.

The Nexavar plus best supportive care to placebo plus best supportive care was compared in the study. The safety and tolerability data were generally as expected.

Bayer HealthCare global clinical development oncology vice president Dimitris Voliotis said, “While we are disappointed that the primary endpoint was not met, we believe the study results will advance the scientific knowledge in lung cancer.”

Nexavar is approved in the US for the treatment of patients with unresectable liver cancer and for the treatment of patients with advanced kidney cancer.